Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)
Public ClinicalTrials.gov record NCT02414139. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Multicenter Study of Oral MET Inhibitor INC280 in Adult Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)
Study identification
- NCT ID
- NCT02414139
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Enrollment
- 373 participants
Conditions and interventions
Conditions
Interventions
- Capmatinib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 10, 2015
- Primary completion
- Apr 11, 2023
- Completion
- May 15, 2023
- Last update posted
- Mar 19, 2024
2015 – 2023
United States locations
- U.S. sites
- 13
- U.S. states
- 10
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pacific Shores Medical Group SC | Long Beach | California | 90813 | — |
| University Of California Los Angeles Dept of Onc | Los Angeles | California | 90095 | — |
| University of California Irvine Medical Center Chao Family Chao Family Comp Cancer Center | Orange | California | 92868 | — |
| H Lee Moffitt Cancer Center and Research Institute . | Tampa | Florida | 33612 | — |
| University of Iowa Hospitals and Clinics SC-3 | Iowa City | Iowa | 52242 | — |
| Massachusetts General Hospital MGH Cancer Center | Boston | Massachusetts | 02114 | — |
| VA Ann Arbor Health System VA Ann Arbor Health System | Ann Arbor | Michigan | 48105 | — |
| Mayo Clinic Rochester . | Rochester | Minnesota | 55905 | — |
| Oregon Health and Science University SC | Portland | Oregon | 97239 | — |
| Lehigh Valley Health Network SC | Allentown | Pennsylvania | 18103 | — |
| Andrew and Patel Associates | Camp Hill | Pennsylvania | 17011 | — |
| Mays Cancer Ctr Uthsa Mdacc SC-5 | San Antonio | Texas | 78229 | — |
| University of Utah / Huntsman Cancer Institute Oncology | Salt Lake City | Utah | 84103 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 82 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02414139, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 19, 2024 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02414139 live on ClinicalTrials.gov.